NCT00275262 · FLOW
Participant flow
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- groups
- description
- Patients received 1 injection of LAD 11.25 mg every 3 months for a total treatment period of 9 months.
- id
- FG000
- title
- Leuprolide Acetate Depot (LAD) 11.25 mg 3 Month
- description
- Patients received 1 injection of placebo every 3 months for a total treatment period of 9 months.
- id
- FG001
- title
- Placebo
- periods
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 2
- group Id
- FG001
- num Subjects
- 0
- type
- Adverse Event
- reasons
- group Id
- FG000
- num Subjects
- 2
- group Id
- FG001
- num Subjects
- 5
- type
- Disease progression
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 2
- type
- Lost to Follow-up
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 2
- type
- Protocol Violation
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 0
- type
- Death
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 0
- type
- Started Chemotherapy
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 12
- group Id
- FG001
- num Subjects
- 13
- type
- STARTED
- achievements
- comment
- Patients who completed the entire 12 month study period
- group Id
- FG000
- num Subjects
- 6
- comment
- Patients who completed the entire 12 month study period
- group Id
- FG001
- num Subjects
- 4
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 6
- group Id
- FG001
- num Subjects
- 9
- type
- NOT COMPLETED
- title
- Overall Study
Complete source fields
- groups
- description
- Patients received 1 injection of LAD 11.25 mg every 3 months for a total treatment period of 9 months.
- id
- FG000
- title
- Leuprolide Acetate Depot (LAD) 11.25 mg 3 Month
- description
- Patients received 1 injection of placebo every 3 months for a total treatment period of 9 months.
- id
- FG001
- title
- Placebo
- periods
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 2
- group Id
- FG001
- num Subjects
- 0
- type
- Adverse Event
- reasons
- group Id
- FG000
- num Subjects
- 2
- group Id
- FG001
- num Subjects
- 5
- type
- Disease progression
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 2
- type
- Lost to Follow-up
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 2
- type
- Protocol Violation
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 0
- type
- Death
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 0
- type
- Started Chemotherapy
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 12
- group Id
- FG001
- num Subjects
- 13
- type
- STARTED
- achievements
- comment
- Patients who completed the entire 12 month study period
- group Id
- FG000
- num Subjects
- 6
- comment
- Patients who completed the entire 12 month study period
- group Id
- FG001
- num Subjects
- 4
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 6
- group Id
- FG001
- num Subjects
- 9
- type
- NOT COMPLETED
- title
- Overall Study
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle